Trial reportGut2024
Simplified
Trial report in Gut, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07788053 (Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple Versus Bismuth Quadruple Therapies For First-Line Eradication of Helicobacter Pylori Infection), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple Versus Bismuth Quadruple Therapies For First-Line Eradication of Helicobacter Pylori Infection: A Single-Center, Randomized Controlled Trial
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Comparing potassium-competitive acid blocker-based therapies forFrontiers in physiology · 2026Pooled it
- Comparison of Keverprazan-based versus esomeprazole-based dual therapy for initial treatment ofAnnals of medicine · 2026Trial
- Vonoprazan-based dual therapy with amoxicillin or doxycycline versus bismuth-containing quadruple therapy forFrontiers in cellular and infection microbiology · 2026Trial
- Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy forPathogens (Basel, Switzerland) · 2025Trial
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
- Trial
- Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Fourteen-Day Vonoprazan-Minocycline vs Vonoprazan-Amoxicillin Dual Therapy for Primary Helicobacter pylori Infection: A Propensity Score Matching Analysis.Clinical and translational gastroenterology · 2026Article
- Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026Review
- A Review on the Progress and Strategies ofGastroenterology research and practice · 2026Review
- Efficacy of Vonoprazan-Doxycycline Dual Therapy for the Treatment ofInfection and drug resistance · 2026Article
- VTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2026Article
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Pathogen virulence genes: Advances, challenges and future directions in infectious disease research (Review).International journal of molecular medicine · 2025Review
- Diagnosis and treatment ofFuture microbiology · 2025Review
- Vonoprazan vs. high-dose esomeprazole in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a retrospective cohort study.Gut pathogens · 2025Article
- 40 years after the discovery ofiMetaOmics · 2025Article
- Article
- Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan forMicroorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThis study aimed to evaluate the efficacy and safety of vonoprazan and tetracycline (VT) dual therapy as first-line treatment for
methodsIn this randomised controlled trial, treatment-naïve adults with
results300 patients were randomised. The eradication rates in the VT group and the BQT group were: 92.0% (138/150, 95% CI 86.1% to 95.6%) and 89.3% (134/150, 95% CI 83.0% to 93.6%) in intention-to-treat analysis (difference 2.7%; 95% CI -4.6% to 10.0%; non-inferiority p=0.000); 94.5% (138/146, 95% CI 89.1% to 97.4%) and 93.1% (134/144, 95% CI 87.3% to 96.4%) in modified intention-to-treat analysis (difference 1.5%; 95% CI -4.9% to 8.0%; non-inferiority p=0.001); 95.1% (135/142, 95% CI 89.7% to 97.8%) and 97.7% (128/131, 95% CI 92.9% to 99.4%) in per-protocol analysis (difference 2.6%; 95% CI -2.9% to 8.3%; non-inferiority p=0.000). The treatment-emergent adverse events (TEAEs) were significantly lower in the VT group (14.0% vs 48.0%, p=0.000), with fewer treatment discontinuations due to TEAEs (2.0% vs 8.7%, p=0.010).
conclusionsVT dual therapy demonstrated efficacy and safety as a first-line treatment for TRIAL REGISTRATION NUMBER: ChiCTR2300074693.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.